Cas No.: | 1417700-13-0 |
Chemical Name: | N-[(1R)-2-(tert-Butylamino)-2-oxo-1-pyridin-3-ylethyl]-N-(4-tert-butylphenyl)furan-2-carboxamide |
Synonyms: | ML188; ML-188; ML 188; |
SMILES: | O1C=CC=C1C(N([C@H](C1=CC=CN=C1)C(NC(C)(C)C)=O)C1=CC=C(C(C)(C)C)C=C1)=O |
Formula: | C26H31N3O3 |
M.Wt: | 433.552 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | ML188, a first in class probe, is a selective non-covalent SARS-CoV 3CLpro inhibitor with an IC50 of 1.5 μM. Antiviral activity[1]. |
In Vitro: | ML188 (0-30 μM; 48 hours) effectively inhibit SARS-CoV replication in cell culture[1]. Probe ML188 is a modest molecular weight SARS-CoV 3CLpro inhibitor with demonstrated antiviral activity and a non-covalent mechanism of action. ML188 yields an antiviral EC50 value ranging from 12.9 to 13.4 μM in mock-infected and SARS-CoV infected cells[1]. Cell Viability Assay[1] Cell Line: Vero E6 cells (mock-infected or infected with SARS-CoV) Concentration: 3, 4, 5, 8,10, 15, 20, 30 μM Incubation Time: 48 hour Result: Against mock-infected and SARS-CoV infected cells. |
References: | [1]. Jacobs J, et al. Discovery, synthesis, and structure-based optimization of a series of N-(tert-butyl)-2-(N-arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL protease. J Med Chem. 2013 Jan 24;56(2):534-46. |